Bing Jiang

Dr. Bing Jiang

Nanozyme Medical Center, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2024 in Nature Reviews Bioengineering
Verified
Journal Article
Closed access
PDF file
RZRuofei Zhang
Ruofei Zhang
Bing JiangBing Jiang
Bing Jiang
Kelong FanKelong Fan
Kelong Fan
LGLizeng Gao
Lizeng Gao
XYXiyun Yan
Xiyun Yan

5 December 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SZShuaibing Zhang
Shuaibing Zhang
XGXuejiao J. Gao
Xuejiao J. Gao
YMYuanjie Ma
Yuanjie Ma
KSKexu Song
Kexu Song
MGMengyue Ge
Mengyue Ge
Bing JiangBing Jiang
Bing Jiang
Iron-based nanozymes, recognized for their biocompatibility and peroxidase-like activities, hold promise as catalysts in tumor therapy. However, their concurrent catalase-like activity undermines therapeutic efficacy by converting hydrogen peroxide in tumor tissues into oxygen, thus diminishing hydroxyl radical production. Addressing this challenge, this study introduces the hemin–cysteine–Fe (HCFe) nanozyme, which exhibits exclusive peroxidase-like activity. Constructed through a supramolecular assembly approach involving Fmoc-l-cysteine, heme, and Fe²⁺ coordination, HCFe distinctly incorporates heme and [Fe–S] within its active center. Sulfur coordination to the central Fe atom of Hemin is crucial in modulating the catalytic preference of the HCFe nanozyme towards peroxidase-like activity. This unique mechanism distinguishes HCFe from other bifunctional iron-based nanozymes, enhancing its catalytic selectivity even beyond that of natural peroxidases. This selective activity allows HCFe to significantly elevate ROS production and exert cytotoxic effects, especially against cisplatin-resistant esophageal squamous cell carcinoma (ESCC) cells and their xenografts in female mice when combined with cisplatin. These findings underscore HCFe’s potential as a crucial component in multimodal cancer therapy, notably in augmenting chemotherapy efficacy.

1 January 2020 in Theranostics
Verified
Journal Article
Open access
Bing JiangBing Jiang
Bing Jiang
LFLong Fang
Long Fang
KWKongming Wu
Kongming Wu
XYXiyun Yan
Xiyun Yan
Kelong FanKelong Fan
Kelong Fan
Nanozymes are a class of nanomaterials with intrinsic enzyme-like characteristics which overcome the limitations of natural enzymes such as high cost, low stability and difficulty to large scale preparation. Nanozymes combine the advantages of chemical catalysts and natural enzymes together, and have exhibited great potential in biomedical applications. However, the size controllable synthesis and targeting modifications of nanozymes are still challenging. Here, we introduce ferritin nanozymes to solve these problems. Ferritins are natural nanozymes which exhibit intrinsic enzyme-like activities (e.g. ferroxidase, peroxidase). In addition, by biomimetically synthesizing nanozymes inside the ferritin protein shells, artificial ferritin nanozymes are introduced, which possess the advantages of versatile self-assembly ferritin nanocage and enzymatic activity of nanozymes. Ferritin nanozymes provide a new horizon for the development of nanozyme in disease targeted theranostics research. The emergence of ferritin nanozyme also inspires us to learn from the natural nanostructures to optimize or rationally design nanozymes. In this review, the intrinsic enzyme-like activities of ferritin and bioengineered synthesis of ferritin nanozyme were summarized. After that, the applications of ferritin nanozymes were covered. Finally, the advantages, challenges and future research directions of advanced ferritin nanozymes for biomedical research were discussed.

19 June 2024 in ACS Nano
Verified
Journal Article
Closed access
YYYunfan Yang
Yunfan Yang
ZLZixiang Li
Zixiang Li
XFXiaochong Fan
Xiaochong Fan
CJChao Jiang
Chao Jiang
JWJunmin Wang
Junmin Wang
JWJian Wang
Jian Wang

19 February 2019 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
Bing JiangBing Jiang
Bing Jiang
LYLiang Yan
Liang Yan
JZJianlin Zhang
Jianlin Zhang
MZMeng Zhou
Meng Zhou
GSGuizhi Shi
Guizhi Shi
XYXiyun Yan
Xiyun Yan

1 January 2019 in Theranostics
Verified
Journal Article
Open access
Bing JiangBing Jiang
Bing Jiang
RZRuofei Zhang
Ruofei Zhang
JZJianlin Zhang
Jianlin Zhang
YHYaxin Hou
Yaxin Hou
XCXuehui Chen
Xuehui Chen
XYXiyun Yan
Xiyun Yan
Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer deaths, primarily due to its high incidence of recurrence and metastasis. Considerable efforts have therefore been undertaken to develop effective therapies; however, effective anti-HCC therapies rely on identification of suitable biomarkers, few of which are currently available for drug targeting.